Turnstone Biologics Restructures with 60% Layoffs and Leadership Changes to Focus on TIL Therapy

Turnstone Biologics is strategically restructuring to concentrate on its tumor-infiltrating lymphocyte (TIL) therapy, leading to a 60% workforce reduction and a significant leadership overhaul. This initiative focuses on advancing the clinical development of its sole clinical-stage candidate, TIDAL-01, targeting colorectal, head and neck, and uveal melanoma[1][2]. The reorganization includes pivotal transitions in C-suite roles, with Michael Burgess retiring as Interim Chief Medical Officer and Ines Verdon assuming the position[2]. As part of this strategic redirection, Turnstone aims to extend its financial viability into 2026 by optimizing resources and prioritizing key pipeline projects[1][2].